NAGLIVAN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	2C11H23N2OS.O.V
Molecular Weight	529.697
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	-4

SHOW SMILES / InChI

Structure Search

SMILES

[O--].[V].CCCCCCCCNC(=O)[C@@H](N)C[S-].CCCCCCCCNC(=O)[C@@H](N)C[S-]

InChI

InChIKey=PTNIVTYIODVYLK-XFMZQWNHSA-L

InChI=1S/2C11H24N2OS.O.V/c2*1-2-3-4-5-6-7-8-13-11(14)10(12)9-15;;/h2*10,15H,2-9,12H2,1H3,(H,13,14);;/q;;-2;/p-2/t2*10-;;/m00../s1

HIDE SMILES / InChI

Description
Sources: https://adisinsight.springer.com/drugs/800001371 | https://www.ncbi.nlm.nih.gov/pubmed/8375263

Naglivan [PMD 501, vanadeine] is a vanadyl organometallic agent, in the preclinical phase of development in France, with Pan Medica, as an orally-active drug for the treatment of diabetes mellitus. Naglivan is an orally effective form of vanadyl with an oral potency 7.6 times greater than that of vanadyl sulfate (minimum effective dose: 0.06 mmol vanadium.kg-1.day-1) as compared to vanadyl sulfate (0.46 mmol vanadium.kg-1.day-1). The lack of incidence of diarrhea in either control or diabetic animals demonstrates that naglivan could be a more therapeutically desirable form of vanadyl.

Originator

Approval Year

PubMed

Title	Date	PubMed
In vivo antidiabetic actions of naglivan, an organic vanadyl compound in streptozotocin-induced diabetes.	1993-05	8375263

Sample Use Guides

In Vivo Use Guide

The antidiabetic effects of naglivan in rats made diabetic with streptozotocin (55 mg/kg, i.v.) were tested. Four days after the streptozotocin injection, one diabetic group (DVI) and a control group (CV) were treated with naglivan (50 mg/kg/day, equivalent to 0.06 mmol vanadium/kg/day) by oral gavage.

Route of Administration: Oral

Name

Type

Language

naglivan [INN]

Preferred Name

English

NAGLIVAN

Official Name

English

OXOVANADIUM(2+), (2R)-2-AMINO-3-(OCTYLAMINO)-3-OXOPROPANE-1-THIOLATE

Systematic Name

English

Code System Code Type Description

EVMPD

SUB09135MIG